All links accessed July 31 2017

1. National Eczema Society - http://www.eczema.org

2. JL Silverberg et al. 'What's in a name? Atopic dermatitis or atopic eczema, but not eczema alone'. Allergy. First published: 30 June 2017 - http://onlinelibrary.wiley.com/doi/10.1111/all.13225/abstract

3. Allergy UK. Eczema and Dermatitis - https://www.allergyuk.org/information-and-advice/conditions-and-symptoms/35-eczema-dermatitis

4. J Schmitt et al. 'Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes'. J Allergy Clin Immunol. January 2016. 137;1: 130€“136. - http://www.jacionline.org/article/S0091-6749(15)00882-9/fulltext

5. RAHM van den Oord and A Sheikh. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ 2009; 339: b2433. - http://www.bmj.com/content/339/bmj.b2433

6. MR Perkin et al. 'Association between domestic water hardness, chlorine, and atopic dermatitis risk in early life: A population-based cross-sectional study'. J Allergy Clin Immunol. August 2016. 138; 2, 509€“516 - http://www.jacionline.org/article/S0091-6749(16)30187-7/fulltext

7. LT Zane et al. 'Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies'. Immunotherapy. July 2016. 8(8):853-66 - https://www.futuremedicine.com/doi/full/10.2217/imt-2016-0023

8. NHS Choices. Atopic eczema. http://www.nhs.uk/Conditions/Eczema-(atopic)/Pages/Introduction.aspx

9. KS Mukkanna et al. 'Para-phenylenediamine allergy: current perspectives on diagnosis and management'. J Asthma Allergy. 2017; 10: 9€“15 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261844/

10. W Uter et al. 'European Surveillance System on Contact Allergies (ESSCA): results with the European baseline series, 2013/14'. J Eur Acad Dermatol Venereol. Published online: 19 June 2017 - http://onlinelibrary.wiley.com/doi/10.1111/jdv.14423/abstract

11. The Cosmetic, Toiletry and Perfumery Association. 'CTPA Annual Report 2016'. - http://www.ctpa.org.uk/annualreport/2016/

12. C. Lifschitz. 'The Impact of Atopic Dermatitis on Quality of Life'. Ann Nutr Metab 2015; 66 (suppl 1): 34-40 - https://www.karger.com/Article/FullText/370226

13. Leeds Institute of Clinical Trials Research, Faculty of Medicine and Health, University of Leeds. ALPHA Patient Zone. http://medhealth.leeds.ac.uk/info/423/skin/1957/alpha_patient_zone

14. FJ Dalgard. 'The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries'. J Invest Dermatol. 2015 Apr; 135(4): 984€“991 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378256/

15. NICE CKS Clinical Knowledge Series. Eczema €“ atopic. Last revised in July 2015 - https://cks.nice.org.uk/eczema-atopic#!topicsummary

16. MHRA. Aqueous cream: may cause skin irritation. Published 25 March 2013 - https://www.gov.uk/drug-safety-update/aqueous-cream-may-cause-skin-irritation

17. eMC - The electronic Medicines Compendium. http://www.medicines.org.uk/emc

18. NICE Clinical Guideline CG57. 'Atopic eczema in under 12s: diagnosis and management'. Published December 2007, last updated October 2013 - https://www.nice.org.uk/guidance/cg57/chapter/1-Guidance

19. NICE Technology appraisal guidance TA82. 'Tacrolimus and pimecrolimus for atopic eczema'. Published date: 25 August 2004.-  https://www.nice.org.uk/guidance/ta82

20. MHRA. 'Oral retinoids: pregnancy prevention€”reminder of measures to minimise teratogenic risk'. June 2013 - https://www.gov.uk/drug-safety-update/oral-retinoids-pregnancy-prevention-reminder-of-measures-to-minimise-teratogenic-risk

21. US Food & Drug Administration. FDA News Release:'FDA approves Eucrisa for eczema'. December 14 2016 - https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm533371.htm

22. SPS - Specialist Pharmacy Service. Medicines Articles: Crisaborole. Published January 8 2016, updated May 16 2017 - https://www.sps.nhs.uk/medicines/crisaborole/

23. AC Cheape and DF Murrell. '2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis'. Expert Review of Clinical Immunology. 2017. 13; 5;415-423 - http://www.tandfonline.com/doi/abs/10.1080/1744666X.2017.1304820?journalCode=ierm20

24. European Medicines Agency - http://www.ema.europa.eu/

25. Sanofi UK. 'Sanofi receives CHMP positive opinion for Dupixent® (dupilumab) to treat adult patients with moderate-to-severe atopic dermatitis'. July 21 2017 - http://www.sanofi.co.uk/l/gb/en/layout.jsp?cnt=16BF96EE-1B5A-40E1-A8AC-7AC2FBAA4C82